Intravitreal bevacizumab versus triamcinolone acetonide for macular edema due to branch retinal vein occlusion: a matched study

• DOI: 10.3760/cma.j.issn.0366-6999.2009.22.004
• Publication Date: 2024-01-16T16:52:08Z
• Authors: Jing HOU; Yong TAO; Yan-rong JIANG; Xiao-xin LI; Lei GAO
• Keywords: Acetonide; Retinal Vein

Background Branch retinal vein occlusion (BRVO) is a common vascular disorder of the elderly and both intravitreal triamcinolone acetonide (TA) bevacizumab were reported to be effective. The purpose this study was compare with TA for treatment macular edema resulting from BRVO. Methods retrospectively comparative interventional included group 34 BRVO patients (1.25 mg bevacizumab) (4.0 TA), two groups matched by baseline best corrected visual acuity (BCVA). Examinations designed carried out at 1 day, 3 days, month, 2 months, 6 months year after each injection. mean follow-up (148.43±130.56) days. Main outcome parameters BCVA morphometric measurements macula obtained optical coherence tomography. Results In all follow-ups, changes (LogMAR) between not significantly different ( P >0.10). Similarly, rates who got improvement ≥ lines or lost different, either groups, compared baseline, central thickness (CMT) reduction 4 weeks initial injection, however, which statistical significance 6-month in =0.25) 3-month =0.07, 0.21). CMT differed <0.01), while almost kept parallel other follow-ups (all >0.40). group, pigment epithelium tear occurred eye 8 injection 12 eyes (35.3%) intraocular pressure >21 mmHg. no severe complications observed. Conclusion For BRVO, versus causes similar increase (except follow-up) minor during year.